The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
AtkinsM.B.HsuJ.LeeS.Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol.2008; 26(35): 5748–2054.
2.
LeghaS.S.RingS.PapdopoulousN.A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer.1989; 64(10): 2024–2029.
3.
EtonO.LeghaS.S.BedikianA.Y.Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol.2002; 20(8): 2045–2052.
4.
BajettaE.Del VecchioM.NovaP.Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol.2006; 17(4): 571–577.
5.
BuzaidA.LeghaS.S.BalchC.M.Pilot study of preoperative chemotherapy with cisplatin, vinblastine, and dacarbazine in patients with local-regional recurrence of melanoma. Cancer.1994; 74(9): 2476–2482.
TrisselL.A.Handbook on Injectable Drugs.15th ed.Bethesda, MD: American Society of Health-System Pharmacists; 2009: 437, 895.
8.
TrisselL.ZhangY.CohenM.The stability of diluted vincristine sulfate used as a deterrent to inadvertent intrathecal injection. Hosp Pharm.2001; 36(7): 740–745.
9.
HeskethP.J.KrisM.G.GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15(1): 103–109.
BaschE.PrestrudA.A.HeskethP.J.American Society of Clinical Oncology Guideline for Antiemetics in Oncology: update 2011. J Clin Oncol.2011; 29(31): 4189–4198.
KrisM.G.GrallaR.J.ClarkR.A.Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol.1985; 3(10): 1379–1384.
14.
GelingO.EichlerH.G.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
15.
TerreyJ.P.AaproM.S.The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
16.
CarmichaelJ.KeizerH.J.CupissolD.MilliezJ.ScheidelP.SchindlerA.E.Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998; 9(5): 381–385.
17.
de WitR.de BoervdA.C.vd LindenG.H.StoterG.SparreboomA.VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 19;85(8): 1099–1101.
18.
SmithIE; Granisetron Study Group. A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. J Cancer Res Clin Oncol.1993; 119(6): 350–354.
19.
SoukopM; Granisetron Study Group. A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Support Care Cancer.1994; 2(3): 177–183.
20.
CornelisonT.L.ReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol.1993; 50(2): 147–158.
21.
KintzelP.E.Anticancer drug-induced kidney. Drug Saf.2001; 24(1): 19–38.
ZanottiK.M.MarkhamM.Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf.2001; 24(10): 767–779.
24.
SmithT.J.KhatcheressianJ.LymanG.H.2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol.2006; 24(19): 3187–3205.
